Skip to main content

Neusignal Therapeutics

Category: AI in Biotech / Drug Discovery

A Tohoku University spin-off developing novel small molecule therapies for Alzheimer's disease, led by drug candidate NTX-083 targeting K-ATP channels. Neusignal Therapeutics was founded in 2022. The company is led by Itaru Arimoto. Based in Tokyo, Japan. Team size: 11-50. Total funding raised: $58.5M. Latest round: Series B. Key investors include Fast Track Initiative, Keio Innovation Initiative, Angel Bridge, DCI Partners, Mitsubishi UFJ Capital, Nissay Capital, Mizuho Capital, SMBC Venture Capital, FFG Venture Business Partners, Red Capital, Nippon Venture Capital, Gogin Capital.

Founded
2022
Headquarters
Tokyo, Japan
Team size
11-50
Total funding
$58.5M

Value proposition

Developing a first-in-class oral small molecule drug for Alzheimer's that simultaneously improves cognitive function, psychiatric symptoms, and suppresses disease progression through a novel mechanism of action, offering a more accessible and affordable treatment option compared to current antibody-based therapies.

Products and solutions

NTX-083 (lead drug candidate): a novel oral small molecule ATP1A3/K-ATP channel inhibitor for Alzheimer's disease with disease-modifying potential, backup compounds and pipeline expansion into new CNS targets.

Unique value

First-in-class oral small molecule targeting K-ATP channels (ATP1A3) for Alzheimer's — combining cognitive improvement, psychiatric symptom relief, and disease modification in a single oral therapy with high safety profile.

Target customer

Alzheimer's disease patients and their caregivers; global pharmaceutical companies for strategic partnerships and licensing.

Industries served

Biotechnology, Pharmaceuticals, Alzheimer's disease / Dementia therapeutics, CNS drug discovery

Technology advantage

Novel mechanism of action (K-ATP channel/ATP1A3 inhibition) discovered by Dr. Shigeki Moriguchi at Tohoku University, published in Molecular Psychiatry (2018); two international patent applications filed; completed GLP toxicology studies; strong safety profile in Phase 1 trials; oral administration enabling at-home treatment; backed by AMED translational research funding.

How they differentiate

Unlike current Alzheimer's treatments (anti-Aβ antibodies like lecanemab/donanemab) which are expensive IV infusions with limited patient access, NTX-083 is an oral small molecule with a novel mechanism targeting K-ATP channels. It aims to simultaneously improve cognitive function, psychiatric symptoms, and modify disease progression. The drug has demonstrated high safety and tolerability in Phase 1 trials in Japan.

Main competitors

Eisai/Biogen (lecanemab/Leqembi), Eli Lilly (donanemab/Kisunla), Anavex Life Sciences (blarcamesine), Cassava Sciences (simufilam)

Key partnerships

Tohoku University (technology origin, licensing), University of Tokyo Hospital (investigator-initiated Phase 1 trial), AMED / Japan Agency for Medical Research and Development (grant funding), Fast Track Initiative (VC and strategic support)

Major milestones

2022-04: Company founded as Tohoku University spin-off, 2024-03: Raised ¥1.33B seed round, 2025-01: Raised ¥2.25B Series A (incl. ¥1.1B AMED grant), 2025-02: Initiated physician-led Phase 1 trial at University of Tokyo Hospital, 2025-09: Completed single-dose Phase 1 (healthy volunteers), 2025-11: Initiated company-sponsored repeat-dose Phase 1 trial, 2026-03: Completed repeat-dose Phase 1 trial with positive safety/tolerability results, 2026-06-30: Raised ¥5.32B Series B for US Phase 1b trial

Growth metrics

11 employees; completed Phase 1 trials in Japan; advancing to US Phase 1b in Alzheimer's patients

Market positioning

Clinical-stage biotechnology company positioned as a next-generation Alzheimer's therapy developer, competing with both traditional symptomatic treatments (donepezil, memantine) and newer disease-modifying antibodies (lecanemab, donanemab) by offering an oral small molecule with combined symptomatic and disease-modifying benefits.

Geographic focus

Japan (current clinical operations); United States (planned Phase 1b trial); global pharmaceutical partnership strategy

Patents and IP

Two international patent applications filed by Tohoku University for NTX-083 (K-ATP channel inhibitor compounds); technology licensed from Tohoku University to Neusignal Therapeutics.

About Itaru Arimoto

Ex-Eisai (9 years as development lead for donepezil, the world's first Alzheimer's drug with ¥300B+ in sales); Ex-Asahi Kasei Pharma (Head of Development & Regulatory Affairs, Head of Overseas Clinical Development, Head of Clinical Planning); Ex-President of Asahi Kasei Group China subsidiary (3.5 years); Ph.D. in Pharmaceutical Sciences from Kyoto University.

Official website: